TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
DUBLIN, Ireland, Feb. 24, 2017 -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2016 on Tuesday, March 14, 2017. The Company has scheduled a conference call for that same day, Tuesday, March 14, 2017 at 11:00am ET (4:00pm GMT) to discuss the results of the quarter.
Interested parties can access the call by dialing:
| USA: | 1-844-861-5499 | |||||||||
| International: | 1-412-317-6581 | |||||||||
| Conference ID #: | 10102284 |
A simultaneous webcast of the call can be accessed at:
https://www.webcaster4.com/Webcast/Page/1135/19990
A replay of the call can be accessed until March 21, 2017 by dialing:
| USA: | 1-877-344-7529 | ||||||||||
| International: | 1-412-317-0088 | ||||||||||
| Conference ID #: | 10102284 | ||||||||||
The webcast of the call will be available for 30 days at:
https://www.webcaster4.com/Webcast/Page/1135/19990
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
Contact: Trinity Biotech plc Kevin Tansley (353)-1-2769800 E-mail: [email protected] Lytham Partners LLC Joe Diaz, Joe Dorame & Robert Blum 602-889-9700
